-+ 0.00%
-+ 0.00%
-+ 0.00%

EU Commission grants marketing approval for Minoryx-Neuraxpharm cALD drug Nezglyal, Kurma Partners says

PUBT·09/29/2026 12:05:48
Listen to the news
EU Commission grants marketing approval for Minoryx-Neuraxpharm cALD drug Nezglyal, Kurma Partners says
  • European Commission granted EU marketing authorization under exceptional circumstances for NEZGLYAL (leriglitazone) to treat pediatric male cALD.
  • Neuraxpharm will commercialize the drug in Europe under a license from Minoryx Therapeutics, a Kurma Partners portfolio company.
  • Approval targets patients aged 2–12 with gadolinium-negative brain lesions; first launch expected in Germany by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kurma Partners SA published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.